Humacyte, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HUMAW | LMAT | AORT | ANGO | ELUT | AVR | |
|---|---|---|---|---|---|---|
| Market cap | — | 1.87B | 1.06B | 476.90M | 35.17M | 602.29M |
| P/E (TTM) | — | 28.8 | — | — | — | — |
| Forward P/E | — | 25.8 | 29.0 | -100.1 | -0.7 | -5.4 |
| Price/book | 0.0 | 4.5 | 2.4 | 2.9 | 2.2 | 2.4 |
| Dividend yield | — | 1.24% | — | — | — | — |
| 1-year change | — | −8.17% | −48.89% | −4.91% | −11.48% | +2.02% |
| Today | −78.05% | +1.39% | −0.28% | +0.89% | +0.66% | +2.15% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All HUMAW news ›Durham’s Humacyte to Present Phase 3 V012 Results for ATEV in Women on Hemodialysis at ASN Kidney Week 2026
Humacyte , a Durham, North Carolina-based commercial-stage biotechnology company developing universally implantable, bioengineered human tissues, announced on October 12, 2026 that interim results from its V012 Phase 3 clinical trial have…
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Profusa Receives ISO 13485:2016 Certificate from GMED New hospital ordering activity increased sequentially each month of the third quarter. Humacyte (HUMA) reported a 44% third-quarter increase in hospitals that have ordered Symvess, its…
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
Humacyte targets an FDA submission this quarter to expand the Symvess label to hemodialysis access. V012 results and two previously completed Phase 3 hemodialysis-access trials form the clinical foundation for a planned supplemental…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
biobuzz.io1
-
stocktitan.net1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.